Urology
Volume 73, Issue 4 , Pages 901-905 , April 2009

Differential Expression of Urocortin in Human Testicular Germ Cells in Course of Spermatogenesis: Role for Urocortin in Male Fertility?

  • Hossein Tezval

      Affiliations

    • Department of Urology and Urological Oncology, Medizinische Hochschule Hannover, Hannover, Germany
    • Corresponding Author InformationReprint requests: Hossein Tezval, M.D., Department of Urology, Medizinische Hochschule Hannover, Carl-Neuberg-Strasse 1, Hannover 30625 Germany
    • ,
  • Axel S. Merseburger

      Affiliations

    • Department of Urology and Urological Oncology, Medizinische Hochschule Hannover, Hannover, Germany
    • ,
  • Jürgen Serth

      Affiliations

    • Department of Urology and Urological Oncology, Medizinische Hochschule Hannover, Hannover, Germany
    • ,
  • Thomas W. Herrmann

      Affiliations

    • Department of Urology and Urological Oncology, Medizinische Hochschule Hannover, Hannover, Germany
    • ,
  • Jan U. Becker

      Affiliations

    • Institute of Pathology, Medizinische Hochschule Hannover, Hannover, Germany
    • ,
  • Olaf Jahn

      Affiliations

    • Max-Planck-Institute of Experimental Medicine, Göttingen, Germany
    • ,
  • Markus A. Kuczyk

      Affiliations

    • Department of Urology and Urological Oncology, Medizinische Hochschule Hannover, Hannover, Germany

Received 18 May 2008 ,Accepted 9 December 2008.

References 

  1. Vaughan J, Donaldson C, Bittencourt J, et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature. 1995;378:287–292
  2. Donaldson CJ, Sutton SW, Perrin MH, et al. Cloning and characterization of human urocortin. Endocrinology. 1996;137:2167–2170
  3. Ruhmann A, Bonk I, Lin CR, et al. Structural requirements for peptide antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2beta-selective antisauvagine-30. Proc Natl Acad Sci USA. 1998;95:15264–15269
  4. Eckart K, Jahn O, Radulovic J, et al. A single amino acid serves as an affinity switch between the receptor and the binding protein of corticotropin-releasing factor: implications for the design of agonists and antagonists. Proc Natl Acad Sci USA. 2001;98:11142–11147
  5. Tezval H, Jahn O, Todorovic C, et al. Cortagine, a specific agonist of corticotropin-releasing factor receptor subtype 1, is anxiogenic and antidepressive in the mouse model. Proc Natl Acad Sci USA. 2004;101:9468–9473
  6. Sehringer B, Zahradnik HP, Simon M, et al. mRNA expression profiles for corticotrophin-releasing hormone, urocortin, CRH-binding protein and CRH receptors in human term gestational tissues determined by real-time quantitative RT-PCR. J Mol Endocrinol. 2004;32:339–348
  7. Florio P, Bruni L, De Falco C, et al. Evaluation of endometrial urocortin secretion for prediction of pregnancy after intrauterine insemination. Clin Chem. 2008;54:350–355
  8. Arcuri F, Cintorino M, Florio P, et al. Expression of urocortin mRNA and peptide in the human prostate and in prostatic adenocarcinoma. Prostate. 2002;52:167–172
  9. Dufau ML, Tinajero JC, Fabbri A. Corticotropin-releasing factor: an antireproductive hormone of the testis. FASEB J. 1993;7:299–307
  10. Heinrich N, Meyer MR, Furkert J, et al. Corticotropin-releasing factor (CRF) agonists stimulate testosterone production in mouse Leydig cells through CRF receptor-1. Endocrinology. 1998;139:651–658
  11. Tao J, Lin M, Sha J, et al. Separate locations of urocortin and its receptors in mouse testis: function in male reproduction and the relevant mechanisms. Cell Physiol Biochem. 2007;19:303–312
  12. Carlson KW, Nawy SS, Wei ET, et al. Inhibition of mouse melanoma cell proliferation by corticotropin-releasing hormone and its analogs. Anticancer Res. 2001;21:1173–1179
  13. Chatzaki E, Lambropoulou M, Constantinidis TC, et al. Corticotropin-releasing factor (CRF) receptor type 2 in the human stomach: protective biological role by inhibition of apoptosis. J Cell Physiol. 2006;209:905–911
  14. Allan DJ, Harmon BV, Roberts SA. Spermatogonial apoptosis has three morphologically recognizable phases and shows no circadian rhythm during normal spermatogenesis in the rat. Cell Prolif. 1992;25:241–250
  15. Bergmann M. [Spermatogenesis—physiology and pathophysiology]. Urol A. 2005;44:1131–1132, 1134-1138
  16. Skinner MK. Cell-cell interactions in the testis. Ann NY Acad Sci. 1987;513:158–171
  17. Saez JM, Avallet O, Lejeune H, et al. Cell-cell communication in the testis. Horm Res. 1991;36:104–115
  18. Fujisawa M. Cell-to-cell cross talk in the testis. Urol Res. 2001;29:144–151
  19. Toyama Y. Actin-like filaments in the myoid cell of the testis. Cell Tissue Res. 1977;177:221–226
  20. Skinner MK, Fetterolf PM, Anthony CT. Purification of a paracrine factor, P-Mod-S, produced by testicular peritubular cells that modulates Sertoli cell function. J Biol Chem. 1988;263:2884–2890
  21. Cigorraga SB, Chemes H, Pellizzari E. Steroidogenic and morphogenic characteristics of human peritubular cells in culture. Biol Reprod. 1994;51:1193–1205
  22. Hadley MA, Byers SW, Suarez-Quian CA, et al. Extracellular matrix regulates Sertoli cell differentiation, testicular cord formation, and germ cell development in vitro. J Cell Biol. 1985;101:1511–1522
  23. Rivier CL. Urocortin 1 inhibits rat Leydig cell function. Endocrinology. 2008;149:6425–6432
  24. Graziani G, Tentori L, Portarena I, et al. CRH inhibits cell growth of human endometrial adenocarcinoma cells via CRH-receptor 1-mediated activation of cAMP-PKA pathway. Endocrinology. 2002;143:807–813
  25. Krishnamurthy H, Weinbauer GF, Aslam H, et al. Quantification of apoptotic testicular germ cells in normal and methoxyacetic acid-treated mice as determined by flow cytometry. J Androl. 1998;19:710–717
  26. Skakkebaek NE, Berthelsen JG, Giwercman A, et al. Carcinoma-in situ of the testis: possible origin from gonocytes and precursor of all types of germ cell tumours except spermatocytoma. Int J Androl. 1987;10:19–28
  27. Honecker F, Stoop H, de Krijger RR, et al. Pathobiological implications of the expression of markers of testicular carcinoma in situ by fetal germ cells. J Pathol. 2004;203:849–857
  28. Florio P, De Falco G, Leucci E, et al. Urocortin expression is downregulated in human endometrial carcinoma. J Endocrinol. 2006;190:99–105
  29. Wang J, Li S. Corticotropin-releasing factor family and its receptors: tumor therapeutic targets?. Biochem Biophys Res Commun. 2007;362:785–788
  30. Hao Z, Huang Y, Cleman J, et al. Urocortin2 inhibits tumor growth via effects on vascularization and cell proliferation. Proc Natl Acad Sci USA. 2008;105:3939–3944

PII: S0090-4295(08)02047-5

doi: 10.1016/j.urology.2008.12.029

Urology
Volume 73, Issue 4 , Pages 901-905 , April 2009

Article Tools

* Image Usage & Resolution